Ewing sarcoma (ES) is the second most common bone tumor in children and young adults, with dismal outcomes for metastatic and relapsed disease. To better understand the molecular pathogenesis of ES and to identify new prognostic markers, we used molecular inversion probes (MIPs) to evaluate copy number alterations (CNAs) and loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded (FFPE) samples, which included 40 ES primary tumors and 12 ES metastatic lesions. CNAs were correlated with clinical features and outcome, and validated by immunohistochemistry (IHC). We identified previously reported CNAs, in addition to A multifactor copy number (MCN)-index was highly predictive of overall survival (39% vs. 100%, P < 0.001). We also identified RELN gene deletions unique to 25% of ES metastatic samples. In summary, we identified both known and novel CNAs using MIP technology for the first time in FFPE samples from patients with ES. CNAs detected by microarray correlate with outcome and may be useful for risk stratification in future clinical trials. Keywords Ewing sarcoma, copy number, outcome, SMARCB1/INI1/SNF5, CEBPB ª 2012 Elsevier Inc. All rights reserved.
associated with poor outcome (10e17). An increased total number of CNAs has been implicated with worse outcome (18e21) ; however, many of these CNA studies were limited by small sample sizes and brief follow-up periods (9, 22) .
Molecular inversion probe (MIP) microarray technology recently has allowed for high-resolution, genome-wide copy number analysis of formalin-fixed paraffin-embedded (FFPE) samples (23e26). This novel genomic technology provides an opportunity to learn about ES molecular genetics because of the wide availability of clinically archived FFPE samples for analysis. Here, we report the first use of MIPs on ES FFPE samples to evaluate CNAs and allelic imbalances. We validate previously reported CNAs and also identify novel CNAs that may be important to ES tumorigenesis and could serve as future therapeutic targets, including unexpected deletions of SMARCB1 (INI1/SNF5). Furthermore, we describe CNA patterns that strongly correlate with event-free survival (EFS) and overall survival (OS) in ES, demonstrating the strength of microarray technology as a possible prognostic tool in this disease.
Materials and methods

Cell lines
Genomic DNA was extracted from five ES cell lines (A673, EWS502, SKNMC, TC32, TC71) and from six healthy individuals as controls. Cell line DNA was run on the Agilent aCGH 44B array (44K tiled probes; Agilent Technologies, Santa Clara, CA) per manufacturer's directions, and 37 ng of cell line and control DNA was submitted for MIP analysis using an initial customized panel of 24,000 cancer gene probes (Affymetrix Research Services Laboratory, Santa Clara, CA). Data from the Agilent aCGH and MIP array platforms were compared using Nexus Copy Number 5.1 (BioDiscovery, Inc., El Segundo, CA).
Clinical sample collection
This study was approved by our Institutional Review Board. De-identified patient material was obtained from the Pathology Department at Primary Children's Medical Center (PCMC), Salt Lake City, Utah. Clinically archived FFPE scrolls were retrieved from 51 individual patients diagnosed with ES between November 1997 and June 2010. Twenty (39%) patients were confirmed by split EWSR1 fluorescence in situ hybridization (FISH) probe, polymerase chain reaction (PCR), or t (11;22) karyogram. Genomic DNA was isolated from the FFPE samples and included 45 primary tumors (PTs), 12 metastatic lesions (MLs, 8 of which were paired to PTs), 5 post-treatment tumor samples (4 paired to PTs), and 1 relapse sample. PT samples were from diagnostic biopsies before chemotherapy. FFPE staging bone marrow aspirate clots were used as paired normal references for each patient when available and negative for tumor. See Supplementary Materials for details on FFPE sample preparation. Clinical factors were extracted from the medical records and included: age, sex, primary tumor site (location and soft tissue vs. bony lesion), metastasis, tumor diameter, tumor percentage and tumor viability of diagnostic biopsy (see Supplementary Table 1) , percentage necrosis at surgical resection, EFS, and OS.
OncoScan FFPE Express assay
Genomic DNA (3e300 ng/sample) from the FFPE clinical samples underwent MIP analysis with the expanded OncoScan FFPE Express assay (V1.0) with 330,000 cancer gene and genome-wide probes (Affymetrix). Each probe in the assay contains 40e60 nucleotides in length that flank the targeted SNP position. Probes were chosen from intragenic sequences of >1,000 genes that have been reported to be specifically involved in cancer development, with the remaining assay probes chosen to fill in the gaps across the genome. This assay provides both copy number and LOH data, and was performed as previously described (24,26e29) . In brief, the entire probe set is introduced to the sample DNA and the following steps are performed as a multiplex reaction: 1) annealing, 2) gap fill polymerization, 3) gap fill ligation, 4) exonuclease selection of unbound probes, 5) release of bound probes, 6) amplification of released probes, 7) probe hybridization to microarray, and 8) microarray scanning. Specific details of this assay can be found in previously published technology reviews (30, 31) .
Data visualization and statistical analysis
Data visualization and CNA analysis was done with Nexus Copy Number 5.1 (BioDiscovery). Univariate and multivariate Cox proportional hazards models were fit to recurring CNAs and regions previously reported to correlate with outcome, with reported P-values from log-rank tests. P-values were adjusted using the Benjamini & Hochberg step-up false discovery rate (FDR) controlling procedure (32) . See Supplementary Materials for details on CNA and statistical analyses.
Immunohistochemical (IHC) staining and analysis
IHC was performed for SMARCB1 (INI-1/BAF-47 antibody; BD Transduction Lab, San Jose, CA) and CEBPB (CEBP beta antibody; Abcam, Cambridge, MA). Results were interpreted by a pathologist (H.H.Z.) blinded to patient identity or CNA results.
Tissue microarrays (TMAs)
A de-identified TMA was obtained from the Children's Oncology Group (COG) that contained 59 tissues from 31 separate ES patients. The COG TMA (3000-30-P8798) was made from a combination of samples collected from biology studies COG B947 and AEWS02B1. Samples were selected based on availability of blocks at the COG bank, and all samples were diagnosed and clinically treated as ES. A second de-indentified TMA was obtained from the University of Michigan (D.L. and D.T.) that contained 44 PTs and 11 recurring MLs, all from individual patients clinically diagnosed and treated as ES. IHC was performed for SMARCB1 protein expression on both TMAs. Results were interpreted by a pathologist (A.R.P.) blinded to patient identity.
Pathology review
Diagnostic hematoxylin and eosin (H & E) slides from samples staining negative for SMARCB1 protein expression were independently reviewed by an anatomic pathologist with expertise in bone and soft tissue sarcomas (A.E.R.). The IHC status of the samples was blinded to the pathologist at the time of the review.
Results
Cell lines
To establish the validity of the MIP array, we compared ES cell lines (n Z 5) run on the Agilent 44K aCGH to the same cell lines run on the original MIP 24K platform. The same gains and losses were seen across both platforms (Supplementary Materials Figure 1 ). The cell lines demonstrated similar CNAs as reported in the literature. Trisomy 8 appeared in 3/5 of cell lines with an additional focal high gain encompassing the MYC gene. 1q amplification was seen in 2/5 of cell lines. Trisomies 12 and 21 were present in 1/5 of cell lines. Expected losses at 9p21 and 16q appeared in 4/5 and 1/5 of cell lines, respectively. These data demonstrate that the MIP platform reliably identifies CNAs in a similar fashion as aCGH.
FFPE clinical samples
Copy number results were derived from 40 FFPE PT samples (5 of the 45 PT samples were excluded due to insufficient DNA quantity) and 32 paired bone marrow aspirate clots that were negative for tumor. See Table 1 for clinical data. Median follow-up length was 3 years (0.7e12.4). Age at diagnosis !10 years old significantly correlated with EFS (P Z 0.015), and the presence of metastatic disease significantly correlated with both EFS and OS (P Z 0.0016 and P Z 0.00033, respectively). No other clinical factors were significantly associated with outcome.
Overall copy number alterations (CNAs)
We analyzed the 40 pre-treatment PTs for recurring CNAs and LOH (Table 2, Supplementary Materials Figure 2 ). In a log-rank test, an excess of three CNAs correlated with outcome when considered as a continuous variable (EFS P Z 0.017, OS P Z 0.00005).
SMARCB1 deletions and LOH
To our surprise, we detected SMARCB1 homozygous deletions in 2 PTs (5%) and focal copy neutral LOH in 1 PT (2.5%) in our Utah cohort. The two homozygous deletions were located within 22q11.23 heterozygous deletions, were quite focal, and spanned 529.1 kilobases (KB) to 1,227.7 KB in length. The common overlapping region of these two focal homozygous deletions was only 53.5 KB in length and included only SMARCB1 and DERL3. The deletion of SMARCB1 was unexpected because SMARCB1 loss is thought to be pathognomonic for rhabdoid tumors (although it can be found in other rare soft tissue sarcomas, as well) (33) . Indeed, lack of SMARCB1 staining is often sufficient for pathologists to revise an unknown pediatric solid tumor diagnosis to a rhabdoid tumor. To confirm the consequence of SMARCB1 deletion or LOH in our sample set, we performed IHC protein staining. The three PTs with SMARCB1 genetic alterations in the Utah cohort showed loss of nuclear SMARCB1 protein expression, while their paired normal bone marrows showed positive nuclear staining, demonstrating that SMARCB1 protein expression loss was a somatic event in these three patients. Twelve additional ES samples (6 PTs þ 6 MLs) that were diploid for SMARCB1 with normal heterozygosity showed retained nuclear positivity with the INI-1/Baf-47 antibody.
Each of these three SMARCB1-negative tumors by IHC was clinically diagnosed and treated as ES based on the histopathology review described below. All three of the SMARCB1-negative tumors in our Utah cohort presented in soft tissue structures (buttock, thigh, and calf), showed "small round cell" histology, occurred in young patients from 1.4 to 10.1 years old (median 5.2), and had EFS of 6 to 10 years with no evidence of disease (NED).
The first SMARCB1-deleted tumor showed sheets of tumor cells with round to oval nuclei, small nucleoli, and small to moderate amounts of eosinophilic cytoplasm. Some tumor cells showed eccentric blobs of eosinophilic cytoplasm. A vague nesting pattern was demarcated by irregular bands of fibrous tissue. Rosettes were not identified. Tumor cells were diffusely reactive for vimentin and focally reactive for AE1/ AE3 cytokeratin, epithelial membrane antigen (EMA), S100, and synaptophysin. The 013 (CD99) showed cytoplasmic blush staining, but no definitive membranous staining. Tumor cells were negative for smooth muscle actin, muscle-specific actin, desmin, myoglobin, and CD45. The karyogram demonstrated a t (11;22) . The histologic appearance, IHC profile, and the t (11;22) led to the clinical interpretation of this tumor as ES with the atypical feature of absence of 013 (CD 99) membranous positivity.
The second SMARCB1-deleted tumor showed sheets of tumor cells with round to oval nuclei, occasional nucleoli, and clear to pale cytoplasm. A vague nesting pattern and zone of hemorrhage and necrosis were noted. A Periodic acid-Schiff (PAS) and PAS with diastase demonstrated abundant cytoplasmic glycogen. Tumor cells were reactive for vimentin, synaptophysin, S100, CD57, and neuron-specific enolase. Focal reactivity was seen with EMA. Tumor cells were negative for HMB45, CD68, muscle-specific actin, desmin, smooth muscle actin, AE1/AE3 cytokeratin, cytokeratin 7, TDT, CD1a, CD20, and 013 (CD99). Chromosome analysis demonstrated a derivative chromosome 22 from a translocation between chromosome 22 and another unknown chromosome. This tumor was classified as an atypical ES based on histology, IHC profile and cytogenetic results.
The third specimen, with SMARCB1 LOH, showed small round uniform tumor cells, with small nucleoli and scanty clear to eosinophilic cytoplasm. No fibrous stroma or rosette formation was identified. Tumor cells showed strong positivity for vimentin and FLI-1. Focal membranous staining was seen with 013 (CD99). EMA and muscle-specific action also showed focal staining. Tumor cells were negative for CD45, myogenin, desmin, and S100. Chromosome analysis demonstrated a normal male karyogram. At the time of diagnosis, this case was seen in consultation by a soft tissue pathologist who concurred with the diagnosis of ES. SMARCB1 protein loss has not been described in ES, so we sought to validate this finding with two independent sets of patient samples. An ES TMA obtained from COG showed a similar rate of SMARCB1 protein expression loss (N Z 3 of 31). The COG tumors originated from the leg, thigh, and scalp/ skull, and also occurred in young patients 10 to 11 years old. Outcome data were not available for the COG tumors.
A second TMA was obtained from the University of Michigan and also demonstrated a similar rate of SMARCB1 protein loss (N Z 3 of 41 primary tumors, and N Z 1 of 10 metastatic/ recurrent tumors). The SMARCB1-negative primary tumors were located in the pelvis (extraosseous), nasal cavity, shoulder (osseous), and the recurrent ML was located in the , and the single SMARCB1-negative recurrent ML occurred in a 20-year-old patient. Two of three SMARCB1-negative PT patients are still alive without disease, and the patient who died presented with the osseous right shoulder tumor. The SMARCB1-negative metastatic patient with the lung lesion was alive with disease (AWD) at the time of last follow-up (>1.5 years since relapse diagnosis). All four of these SMARCB1-negative tumors from the University of Michigan were signed out as primitive neuroectodermal tumor (PNET)/Ewing sarcoma based on morphology. These SMARCB1-negative tumors (N Z 10 [3 from Utah, 3 from COG, and 4 from Michigan]) were from archived clinical samples, and only the Michigan samples were available for molecular testing to further confirm the diagnosis of ES. However, H&E slides were obtained from each of these samples along with clinical pathology reports and sent for blind review by an expert bone tumor pathologist. Upon review, it was felt that 4 out of 10 of these tumors represented "Conventional ES" (2 from COG, 2 from Michigan), and the remaining 6 tumors were "Atypical ES" with a mixture of large cells with abundant clear cytoplasm (largecell ES), spindle cells, and intermittent rhabdoid-appearing cells. Of note, none of the atypical cases appeared to look like classic soft-tissue rhabdoid tumors. Both of the conventional-appearing ES tumors from Michigan that were SMARCB1-negative were found to be positive for EWSR1 rearrangement by FISH using a break-apart probe, and the two atypical cases were FISH negative. See Supplementary Table 2 for individual descriptions of all 10 of the SMARCB1-negative tumors.
Taken together, these data demonstrate that SMARCB1 protein loss may be found in a very small proportion of conventional ES, and that another small proportion of atypical (or large-cell) ES may contain SMARCB1 loss. Due to the presence of rhabdoid-appearing cells mixed with ES large cells, this latter subset may represent a rare but novel type of hybrid ES-rhabdoid tumor that requires further investigation. See Figure 1 for SMARCB1 staining results on diagnostic samples. Table 3 summarizes the recurring CNAs that correlated with outcome. Chromosome 20q showed trisomy in 15% (n Z 6 of 40) of PTs. Two separate and focal regions in 20q showed additional gains in two different patients. The first focal gain on 20q13.2 contains three genes (ZNF217, SUMO1P1, and BCAS1) and was the most significant CNA region to predict poor outcome (EFS P Z 0.00033, OS P Z 1.9E-7). The second focal region on 20q13.13 contained a very high gain (11 copies) within the trisomy 20q centered on CEBPB (CCAAT/enhancer binding protein beta). IHC showed increased or equal CEBPB nuclear staining in the ES tumors with CEBPB (20q) gain compared to ES tumors without CEBPB gains and a non-tumor control. The ES sample with the high gain of 11 copies showed the darkest IHC nuclear staining (Figure 2) . CEBPB gains correlated with worse outcome (EFS P Z 0.012, OS P Z 0.00013).
Additional CNAs and outcome
CEBPB regulates cellular growth and differentiation, and is involved in collagen synthesis (34) and chondrocyte terminal differentiation (35) . CEBPB also has been implicated in increased bone reabsorption through the RANKL pathway in giant-cell tumors (36) . Interestingly, the primary sites of cases with CEBPB amplification in our cohort occurred exclusively in bone (femur, fibula, pelvis, rib, L7 vertebra). We examined cases with CEBPB gains for bone destruction and found four cases presented with no evidence of bone destruction, one case contained notable bone destruction, and one case had no available data. These results lead us to believe that while CEBPB gains may be related to occurrence in bone, it does not appear to be linked to bone destruction. Our data set showed RANKL amplification in only one case, which also coincided with CEBPB amplification but no bone destruction.
Previous studies have linked 16q with survival outcomes (13). Our Utah cohort contained recurring, focal deletions in 16q24.1 and 16q23.3e24.1 that marginally correlated with EFS (P Z 0.014 and 0.041, respectively) and OS (P Z 0.030 and 0.10, respectively). Trisomy 8 also has been reported to correlate with worse outcome, with C-MYC as a suspected driver linked to poor prognosis (12,37); 40% of our cohort contained full or partial trisomy 8, including one patient with a focal C-MYC gain. Full or partial trisomy 8 correlated with outcome (EFS P Z 0.032, OS P Z 0.00038), and this significance increases when including the focal C-MYC gain (EFS P Z 0.0059, OS P Z 0.0000174). Trisomy 5 is not commonly reported in ES, but our cohort contained three patients (7.5%) with a full trisomy. All three patients were >10 years old (16.9, 17.8, and 20.6 years old), two of three presented with metastasis, and all of them relapsed and/or died (EFS P Z 0.01, OS P Z 0.0027).
Only 5% of our PTs showed 9p21 (CDKN2A) loss, lower than the reported ranges of 13e56% (10,38); 80% of the ES cell lines showed CDKN2A deletions, and this higher rate previously has been observed in cell lines (17) . The 9p21 loss has been linked to negative outcome (15) , but both patients with CDKN2A deletions in our cohort presented without metastasis and have not relapsed more than two and a half years after diagnosis. Our limited number of CDKN2A deletions is too small to determine the true correlation with outcome. Current studies validating the prevalence and prognostic significance of CDKN2A deletions in ES are under way through COG.
We combined all significant CNA regions correlating with outcome from our unadjusted analyses into a "multifactor copy number (MCN) index" with at least one affected region. The MCN-index significantly correlated with worse EFS (P Z 0.013) and OS (P Z 0.00059) (Figure 3) . The MCNindex still predicted OS (P Z 0.03), even when using the extremely stringent bootstrapping analysis technique. See Supplementary Materials for more details on the bootstrapping statistical approach used in the MCN analysis.
Metastatic lesions (MLs)
Analysis of paired MLs from archived FFPE samples allowed us to recognize acquired lesions at relapse (see Figure) . In addition, we compared the 30 PTs without metastases to the 12 MLs in order to identify differences unique to MLs using the two-tailed Fisher exact test. Two regions were found to be significant including an allelic imbalance in 7q22.1 (0% PTs vs. 25% MLs, P Z 0.0192) and a gain in 12p12.3ep12.2 (7% PTs vs. 42% MLs, P Z 0.0138). No other regions reached statistical significance, see Supplementary Material Figure 3 . Further investigation of the 7q22.1 allelic imbalance revealed a nearly 1 MB region deleted in 2 ML samples and copy neutral LOH in 1 ML sample (n Z 3 of 12, 25%). Only one PT contained this same 7q22.1 deletion and it was the PT paired to the ML with the same deletion. The 12p12.3ep12.2 gain contained only a single predicted gene of unknown function. The focal 7q22.1 region contained 10 unique genes including the RELN (reelin) gene. The reduced expression of RELN has been implicated in other tumor types such as hepatocellular (39) , pancreatic (40) , and gastric carcinomas (41, 42) .
Discussion
The introduction of genome-wide, high-resolution SNP microarray technology has led to the discovery of CNAs in a variety of common tumors such as breast cancer (43), ovarian cancer (44), lung cancer (45), glioblastoma (46) , neuroblastoma (47, 48) , pediatric astrocytoma (28, 49) , and acute lymphoblastic leukemia (ALL) (29, 50, 51) . These copy number studies identified specific genes and molecular pathways that have emerged as prognostic markers and therapeutic targets, such as the IKZF1 gene and the JAK-STAT signaling pathway in childhood ALL (52, 53) . CNA investigations by new technologies continue to lead to clinical improvement in the common cancers readily available for analysis. The less common cancers, such as ES, have not been as thoroughly investigated by SNP microarray technologies. . Panel B displays CEBPB IHC for same sample; note the extremely intense and diffuse nuclear staining in EWS-19 (copy number 11) compared to the relatively strong nuclear staining in EWS-32 (ES tumor with three copies), and two ES tumors with less diffuse, lighter staining and normal CEBPB copy number (EWS-44 and EWS-27). Panels C and D display the EFS and OS for the Ewing sarcoma patients within our Utah cohort, with and without the focal 20q13.13 gain that contains the CEBPB gene (P Z 0.012, P Z 0.00013, respectively).
The limited number of published CNA studies in ES inconsistently correlate their findings with outcome, most likely due to relatively small sample sizes and differing resolution of aCGH platforms (17) . With ES survival ranging between 10e30% for metastatic or relapsed disease (6, 7) , the identification of new molecular candidates for risk stratification and therapeutic targets remains imperative for this still deadly disease. In this study, we take advantage of novel MIP technology to analyze clinically archived FFPE diagnostic, metastatic, and post-treatment ES samples that have been accumulating for many years. These FFPE specimens originated from previously treated patients at our institution and so we were able to correlate our molecular findings with clinical factors in the medical record.
The most unexpected finding of our study was the identification and validation of SMARCB1 protein loss in up to 10% of samples initially diagnosed as ES. Inactivation and loss of the tumor suppressor SMARCB1 defines the diagnosis of softtissue rhabdoid tumors and atypical teratoid/rhabdoid tumors (ATRTs), but has never been reported in ES despite initial studies that looked for it (54e56). The previous inability to detect SMARCB1 loss in ES may have been due to the quality of the initial antibodies used or the small number of ES cases investigated. In rhabdoid tumors, SMARCB1 inactivation can occur through predisposing germline mutations or deletions (15e20%) as well as somatic changes (65%) (54) . Loss of SMARCB1 protein expression has been linked to other tumors such as myxoid (56) and poorly differentiated chordomas (57), epithelioid sarcomas (58, 59) , epithelioid malignant peripheral nerve sheath tumors (MPNSTs) (32) , renal medullary carcinomas (60), pediatric undifferentiated soft tissue sarcomas (61) , and hepatoblastoma (62) . In one study, a similar gene SMARCA5, also responsible for chromatin remodeling, was found to be a novel fusion product with EWSR1 in a t(4;22)(q31;q12) (63) , but the gene was not deleted.
All patients in our cohort were clinically diagnosed and treated for ES. Two of the SMARCB1-negative patients from Utah and two of the SMARCB1-negative patients from the Michigan cohort contained what appear to be EWSR1-translocations. Upon blinded review of all 10 SMARCB1-negative tumors from all three cohorts, an anatomic pathologist with expertise in bone tumors and soft tissue sarcomas agreed that 40% (4 of 10) of these tumors appeared to be conventional in their histology for ES, and 2 of these contained classic staining for ES; the remaining 6 tumors (despite being clinically diagnosed and treated as ES) were atypical with a mixture of large cell ES and rhabdoid-like tumor cells. Of note, despite the presence of rhabdoid cells in some of these atypical ES cases, the pathologist did not believe these specimens were classic for the diagnosis of malignant rhabdoid tumors.
All SMARCB1-negative samples in the pediatric cohorts (3 Utah þ 3 COG) came from patients 11 years old (mean 8 years old)dyounger than the typical adolescent and young adult commonly diagnosed with ES (2,3). The Michigan TMA included adult patients and was skewed to patients older than the Utah or COG pediatric cohorts, so it is difficult to evaluate the effect of age in the SMARCB1-negative patients in the Michigan TMA. Eight of the total SMARCB1-negative tumors (80%) in all three cohorts presented in soft tissue structures, and one of the two osseous tumors presented in both the scalp and skull; this extraskeletal predominant presentation in SMARCB1-negative ES is reminiscent of rhabdoid tumor and may represent a common underlying molecular mechanism of tumorigenesis in soft tissue. Outcome data was unavailable from the COG patients, but all 3 of the SMARCB1-negative patients from the Utah pediatric cohort and 2 of 3 SMARCB1-negative PT patients in the Michigan cohort are alive without relapse or disease and the 1 ML patient is currently AWD. This high rate of survival would be unexpected in traditional rhabdoid diagnoses. Perhaps the combination of EWSR1-translocations with SMARCB1 loss confers susceptibility to treatment, or the specific ES therapy could have contributed to the favorable outcome in these patients.
Ultimately, the diagnosis of ES, similar to any other tumor, needs to be based upon careful histopathology, immunohistochemical, and genetic examination. The samples for this study were obtained from clinical archives (Utah) or part of external TMAs (COG, Michigan), so we were unable to perform adequate molecular studies to confirm the diagnosis of ES in all of the SMARCB1-deleted tumors. Nevertheless, careful review by an expert pathologist in bone tumors confirmed that at least 40% of these tumors appeared to be "conventional ES" under the microscope (two of which contained FISH evidence for EWSR1 rearrangement), and most of the remaining 60% contained large-cell ES mixed with a variety of spindle and rhabdoid cells. We believe, therefore, that the possibility must be considered that this unique set of tumors represents atypical ES, atypical rhabdoid tumors, or some hybrid combination of both ES-rhabdoid tumors. The SMARCB1 loss may be a secondary finding, which could be subsequent to the primary EWSR1 rearrangement. Perhaps the chromosome 22 is unstable, leading to both alterations within a single tumor. We are now collecting more cases of atypical ES for further genomic scrutiny of the SMARCB1 region.
Other CNAs detected in our study have been previously described in the ES copy number literature, including gains in chromosomes 8, 12, 20, and 1q as well as losses in 16q and 9p21. Using MIP technology, we narrowed 20q gains to smaller, focal regions in 20q13.12 and 20q13.13, and 16q losses to 16q24.1 and 16q23.3e24.1. We demonstrated that increased CEBPB copy number in the 20q13.13 gain correlates with increased nuclear staining and presumably function. Further exploration of the connection between CEBPB gains, biological function, and outcome are now required. We also identified the novel finding of trisomy 5 in older patients with metastatic disease and worse outcome. Many of the genes found within these CNA regions, including SMARCB1, can now be targeted in the laboratory for a better understanding of ES development and progression.
Many of our candidate regions reached only marginal significance when correlated with outcome, especially when adjusting for metastasis and age. We therefore developed a more robust model for outcome prediction by combining these multiple CNAs into a single variable for risk (MCNindex). The MCN-index maintained significance for OS even when using the very strict bootstrapping statistical method. In our cohort, survival was 100% for patients without any CNAs in the MCN-index (20q13.2 gain, 20q13. 13 [CEBPB] gain, MYC gain, 16q24.1 deletion, 16q23.3e24.1 deletion, Trisomy 5, Trisomy 8, Trisomy 20). It would be useful to apply the MCN-index analysis to a larger number of clinically annotated, well-characterized cohorts of patients to determine its prognostic value in different clinical and genetic groups. If validated in larger cohorts, the use of the MCNindex to accurately identify ES patients at low risk for relapse could be helpful with clinical trial design and the potential to selectively decrease therapeutic intensity in these patients.
We also studied a relatively large number of metastatic samples in our cohort; 25% of our ML samples contained genetic alterations in the RELN gene compared to none of the PTs without metastasis. RELN encodes an extracellular protein that regulates cellecell interactions critical for cell positioning and neuronal migration during brain development (64, 65) . In breast cancer, promoter methylation controls RELN expression, and decreased expression has been linked to increased invasiveness and metastatic potential (66) . We believe RELN deletions may be informative about ES metastatic biology, but also can serve as a potential therapeutic candidate for further investigation. Efforts are now under way to collect more of these rare metastatic lesions from ES patients to increase sample size and the likelihood of finding recurrent genomic alterations in MLs. The ability to target metastatic-specific lesions would be very helpful in ES due to limited therapeutic options and poor survival for patients with widespread disease.
In this study, we demonstrate that MIP technology can evaluate molecular alterations in clinically archived FFPE samples in ES. We identified both novel and known CNAs, including the novel finding of SMARCB1 alterations and protein loss in a unique subset of patients clinically diagnosed as ES. These unusual SMARCB1-negative tumors may represent atypical cases of large cell ES or perhaps a hybrid of ES-rhabdoid tumors. Finally, we created an MCNindex based on genome-wide microarray findings that identified 100% of surviving patients versus less than 40% who relapsed and died. As these findings are replicated in future studies, genome-wide microarray technology may hold a useful place for patient risk stratification and therapeutic target identification in ES. 
